SARS
SARS company profile
Latest price
As of — · Market data by Massive
Market cap
—
Volume
—
Previous close
—
Day range
—
Listed
—
Coverage
14 articles
Price performance
Recent trading
Newsroom
Latest SARS coverage
COVID-19 may trigger new-onset high blood pressure
[ad_1] Research Highlights: An analysis of more than 45,000 people infected with SARS-CoV-2 found a significant association between the virus and the development of persistent high blood pressure among those with no prior history of high blood pressure. In addition, people with COVID-19 infection and no history of high blood pressure were significantly
New CPR guidance addresses more contagious COVID-19 variants amidst evolving pandemic
[ad_1] (NewMediaWire) – January 24, 2022 – DALLAS – In response to the COVID-19 pandemic, the American Heart Association and collaborating organizations, including the American Academy of Pediatrics, the American Association for Respiratory Care, the Society of Critical Care Anesthesiologists and the American Society of Anesthesiologists, c
CBD Fights Covid, The Hemp Collect Suggests Live Resin
[ad_1] Hemp compounds, CBDa and CBGa positively impact SARS-CoV-2 infections but this is not the same as CBD and CBG warns The Hemp Collect. Portland, Oregon – (NewMediaWire) – January 13, 2022 – In a newly published study, researchers have found that cannabidiol and cannabigerol, commonly known as CBD and CBG, may limit the reproduction ..
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development
Shelton, Connecticut – September 14, 2019 — NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that it has completed the process of licensing the human Coronavirus field for drug development and commercialization from TheraCour Pharma, Inc. (“TheraCour”). The Company executed
Applied UV Announces Laboratory Results Confirm SteriLumen’s Lumicide™ Ribbon Kills SARS-CoV-2 (COVID-19 Virus)
Previously reported independent lab results confirmed killing OC43 human coronavirus ("OC43"), a common surrogate for SARS-CoV-2, the virus that causes COVID-19 Mount Vernon, NY // June 16, 2021 – Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), an infection control technology company that applies the power of narrow-range ultraviolet light
Sigyn Therapeutics(TM) Discloses In-Vitro Viral Pathogen Study
[ad_1] Sigyn Therapy™ demonstrates the ability to address viral pathogens, including SARS-CoV-2 (COVID-19) SAN DIEGO, CA – (NewMediaWire) – April 21, 2021 – Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by Cytokine St
EMBARGOED Media Alert: Athletes unlikely to develop cardiac complications from COVID, study shows
[ad_1] Highlights: To date, no adverse cardiac events related to SARS-CoV-2 infection have been observed among more than 3,000 collegiate athletes during short-term clinical surveillance. Findings suggest safe return-to-play without cardiac testing for asymptomatic or mildly symptomatic athletes. Embargoed until 12:00 p.m. CDT / 1:00 p.m. EDT April 17, 2021
Menon Qualifies for XPRIZE Alumni Network With Molecular Mirror Platform Technology
[ad_1] Molecular Mirror™ Detection Technology Allows for Screening of More Than 100,000 Patient Specimens Per Day Using Standard MRI Systems Available in Hospitals San Diego, CA – (NewMediaWire) – March 31, 2021 – Menon Biosensors, Inc. ("Menon" or the "Company"), a subsidiary of Menon International, Inc., a distributive technology portfoli
GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update
[ad_1] COVID-19 Vaccine Designed as Single-Dose Against Multiple Strains Immuno-Oncology Programs Advancing Atlanta, GA – (NewMediaWire) – March 23, 2021 – GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced its financial results for the
Sigyn Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
[ad_1] San Diego – (NewMediaWire) – March 8, 2021 – Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today announced that Jim Joyce, its Chairman and Chief Executive
GeoVax Expands and Strengthens Intellectual Property Portfolio
[ad_1] Filings Made in Corporate Focus Areas of SARS-CoV-2 and Immuno-Oncology Atlanta, GA – (NewMediaWire) – March 4, 2021 – GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the filing of two addition
Global WholeHealth Partners, Corp (GWHP: OTC) Announces the Beginning Research for Saliva COVID 19 SARS 2 Antigen (N+S) Tests
[ad_1] Dr. Shujie Cui has developed a (N+S) Antigen test with great sensitivity and is planning to create the first Saliva N+S Antigen Test San Clemente, CA – (NewMediaWire) – January 15, 2021 – Mr. Strongo, CEO of Global WholeHealth Partners Corp, has encouraged the increase in R&D to make Global the leader in the ...
Additional $400K awarded for fast-tracked COVID-19 heart and brain health research
[ad_1] (NewMediaWire) – August 10, 2020 – DALLAS – The American Heart Association has awarded an additional $400,000 in research grants focused on the cardiovascular impact of COVID-19. The awards go to four more teams who submitted proposals for the COVID-19 and Its Cardiovascular Impact Rapid Response Grants during the original submission
These Eye Problems Could Be Symptoms Of COVID-19 Coronavirus
Looks like the eyes may have it. You know those round things that sit below your forehead and you use to “wink and gun” at people? Well, add them to the growing list of body parts that may be affected by the COVID-19 coronavirus. A study recently published in JAMA Ophthalmology found that 31.6% of 38 consecutive patients with COVID-19 ...